CompletedPhase 1NCT02426229

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Medical University of South Carolina
Principal Investigator
Richard M Silver, MD
Medical University of South Carolina
Intervention
dabigatran etexilate(drug)
Enrollment
15 enrolled
Eligibility
18-70 years · All sexes
Timeline
20162018

Study locations (1)

Collaborators

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02426229 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials